MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, M. R.
Right arrow Articles by Chung, I. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, M. R.
Right arrow Articles by Chung, I. K.

Vol. 61, Issue 4, 879-884, April 2002

Down-Regulation of DNA Topoisomerase IIalpha in Human Colorectal Carcinoma Cells Resistant to a Protoberberine Alkaloid, Berberrubine

Mi Ran Kang and In Kwon Chung

Department of Biology, College of Science, and Protein Network Research Center, Yonsei University, Seoul, Korea

Berberrubine, a protoberberine alkaloid that exhibits antitumor activity in animal models, has been identified as a specific poison of DNA topoisomerase II in vitro. To better understand the mechanisms of cellular response to berberrubine, human colorectal carcinoma cells (AMC5) were selected for resistance to berberrubine. The resulting cell line (AMC5/B1) was 5.3-fold resistant to berberrubine in the absence of MDR1 overexpression. The AMC5/B1 line was cross-resistant to topoisomerase II-targeted drugs but showed no cross-resistance to other antitumor drugs. The patterns of cross-resistance to various drugs led us to examine the cellular contents of topoisomerase II. Topoisomerase II activity was ~2.8-fold lower in AMC5/B1 cells compared with parental cells. The AMC5/B1 line contained ~5-fold decrease in topoisomerase IIalpha protein level and ~2.5-fold decrease in topoisomerase IIalpha mRNA level. A comparison of the degradation kinetics of topoisomerase IIalpha mRNA demonstrated that there was no difference in mRNA stability between the two cell lines. Furthermore, the activity of topoisomerase IIalpha promoter in AMC5/B1 cells was about 25% of that in AMC5 parental cells when transient transfection experiments were performed with the promoter-luciferase reporter gene. These results indicate that down-regulation of topoisomerase IIalpha in AMC5/B1 cells occurs at the transcriptional level. Nucleotide sequencing of the topoisomerase IIalpha promoter regions revealed no mutations in AMC5/B1 cells. In summary, resistance to berberrubine in AMC5 cells is associated with decreased level of catalytically active topoisomerase IIalpha , suggesting that topoisomerase IIalpha is the cellular target of berberrubine in vivo.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Cancer Res.Home page
M. K. Pandey, B. Sung, A. B. Kunnumakkara, G. Sethi, M. M. Chaturvedi, and B. B. Aggarwal
Berberine Modifies Cysteine 179 of I{kappa}B{alpha} Kinase, Suppresses Nuclear Factor-{kappa}B-Regulated Antiapoptotic Gene Products, and Potentiates Apoptosis
Cancer Res., July 1, 2008; 68(13): 5370 - 5379.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. H. Kim, J. H. Kim, G. E. Lee, J. E. Lee, and I. K. Chung
Potent Inhibition of Human Telomerase by Nitrostyrene Derivatives
Mol. Pharmacol., May 1, 2003; 63(5): 1117 - 1124.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics